Xenon
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Xenon
- Molecular weight
- 131.29
- Structure (SMILES)
These details could not be displayed.
- xenon
- Xenon
- XENON [JAN]
- XENON [MART.]
- XENON [MI]
- XENON [VANDF]
- Xenon [WHO-DD]
- xenon jan
- xenon mart
- xenon mi
- xenon vandf
- xenon who dd
- CAS registry numbers
- 7440-63-3
- ChEMBL ID
- CHEMBL1236802
- InChIKey
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N
- RxNorm IDs (RxCUI)
- 11363
- FDA ingredient codes (UNII)
- 3H3U766W84
- N01AX15
- V04CX12
Sources for recorded values
- 23991
- 175671520
- 175671525
- 175671534
- Applicant
- CURIUM
- Approval date
- 9 Mar 1982
- Application number
- NDA018327
- First in class
- Yes
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Parenteral
- topical
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Obsessive-Compulsive Disorder
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004242
- Subject identifier
- D009771
- Condition
- Panic Disorder
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004262
- Subject identifier
- D016584
- Condition
- Delirium
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009267
- Subject identifier
- D003693
- Condition
- Hypothermia
- Highest recorded phase
- 2
- Condition identifier
- HP:0002045
- Subject identifier
- D007035
- Condition
- Ischemic Stroke
- Highest recorded phase
- 3
- Condition identifier
- HP:0002140
- Subject identifier
- D000083242
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Bipolar Disorder
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0004985
- Subject identifier
- D001714
- Condition
- Brain Ischemia
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005299
- Subject identifier
- D002545
- Condition
- Cystic Fibrosis
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0009061
- Subject identifier
- D003550
- Condition
- Brain Injuries
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0043510
- Subject identifier
- D001930
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001645
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004242
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004244
- Condition identifier
- EFO_0004262
- Condition identifier
- EFO_0004610
- Condition identifier
- EFO_0009267
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009492
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009833
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009954
- Highest recorded phase
- 2
- Condition identifier
- HP_0000739
- Highest recorded phase
- 1
- Condition identifier
- HP_0002045
- Highest recorded phase
- 2
- Condition identifier
- HP_0002140
- Highest recorded phase
- 3
- Condition identifier
- HP_0002647
- Condition identifier
- MONDO_0002009
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004985
- Condition identifier
- MONDO_0004985
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005010
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005258
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005299
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005383
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006663
- Highest recorded phase
- 2
And 4 more, listed on the interactive page.
- NCT00879892
- NCT00934700
- NCT01545271
- NCT02071394
- NCT01120405
- NCT01285271
- NCT01757106
- NCT01948765
- NCT01199276
- NCT01262729
- NCT02098148
- NCT02220426
- NCT03482960
- NCT03748446
- NCT03764163
- NCT05433961
- NCT04432155
- NCT05335109
- Dose
- 75-100mL
- Route
- Inhalation
- How often
- As needed
- Administer dose within 5 minutes of DE measurement
- Inhale the entire contents of one Dose Delivery Bag
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 1
- Molecular formula
- Xe
- Monoisotopic mass
- 131.90415508
- Natural product
- No
- Anesthetics, Inhalation
Related records
Trials (54)
- A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon
- A Test of Neural Inertia in Humans With Xenon
- Anesthesia for Obese Patients: Desflurane Versus Xenon
- Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI
- Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery
- Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair
- Depth of Hypnosis and Postoperative Nausea and Vomiting During Xenon Anaesthesia
- Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
- Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
- Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
- Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
- Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
- Evaluation of Brain Damage Resulting From Carotid Endarterectomy With Xenon Anesthesia
- Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease
- Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
- Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
- Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
- General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.
- Hemodynamic Stability During Carotid Endarterectomy.Comparison of LENOXe™ (Xenon 100% v/v) Versus Sevoflurane
- Hip Fracture Surgery in Elderly Patients
In development for (12)
- Bipolar disorder Early phase 1
- Brain injury Phase 2
- Brain ischemia Phase 2
- Chronic obstructive pulmonary disease Phase 1
- Coronary artery disorder Phase 3
- Cystic fibrosis Early phase 1
- Delirium Phase 2
- Ischemic stroke Phase 3
- Major depressive disorder Early phase 1
- Obesity disorder Phase 1
- Obsessive-compulsive disorder Phase 2
- Panic disorder Phase 2